Annovis Bio (ANVS) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

ANVS Stock Forecast


Annovis Bio stock forecast is as follows: an average price target of $25.67 (represents a 194.04% upside from ANVS’s last price of $8.73) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ANVS Price Target


The average price target for Annovis Bio (ANVS) is $25.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $21.00. This represents a potential 194.04% upside from ANVS's last price of $8.73.

ANVS Analyst Ratings


Buy

According to 4 Wall Street analysts, Annovis Bio's rating consensus is 'Buy'. The analyst rating breakdown for ANVS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Annovis Bio Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Raghuram SelvarajuH.C. Wainwright$30.00$8.82240.14%243.64%
Aug 13, 2024Jason KolbertEF Hutton$21.00$7.87166.84%140.55%
Apr 30, 2024Sumant KulkarniCanaccord Genuity$26.00$7.28257.14%197.82%
Row per page
Go to

The latest Annovis Bio stock forecast, released on Oct 16, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $30.00, which represents a 240.14% increase from the stock price at the time of the forecast ($8.82), and a 243.64% increase from ANVS last price ($8.73).

Annovis Bio Price Target by Period


1M3M12M
# Anlaysts123
Avg Price Target$30.00$25.50$25.67
Last Closing Price$8.73$8.73$8.73
Upside/Downside243.64%192.10%194.04%

In the current month, the average price target of Annovis Bio stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 243.64% increase as opposed to Annovis Bio's last price of $8.73. This month's average price target is up 17.65% compared to last quarter, and up 16.87% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024H.C. WainwrightBuyBuyHold
Sep 03, 2024Canaccord GenuityBuyBuyHold
Aug 13, 2024EF Hutton-BuyInitialise
Jul 11, 2024H.C. WainwrightBuyBuyHold
Jul 02, 2024Rodman & RenshawBuyBuyHold
Jun 04, 2024Rodman & Renshaw-BuyInitialise
Row per page
Go to

Annovis Bio's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company gave ANVS a "Buy" rating, the same as its previous rate.

Annovis Bio Financial Forecast


Annovis Bio Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------------------
Avg Forecast$12.12M$11.44M$11.21M$10.98M---------------
High Forecast$12.12M$11.44M$11.21M$10.98M---------------
Low Forecast$12.12M$11.44M$11.21M$10.98M---------------
# Analysts1111---------------
Surprise %-------------------

Annovis Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Annovis Bio EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
EBITDA-------------------
Avg Forecast-------------------
High Forecast-------------------
Low Forecast-------------------
Surprise %-------------------

undefined analysts predict ANVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Annovis Bio's previous annual EBITDA (undefined) of $NaN.

Annovis Bio Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
Net Income-------------------
Avg Forecast$248.77K$316.62K$398.03K$309.83K$-1.76M$-1.59M$-1.48M$-4.80M$-1.80M$-1.62M$-1.51M$-1.59M$-5.01M$-4.35M$-4.11M$-3.63M$-4.38M$-5.72M$-7.10M
High Forecast$248.77K$316.62K$398.03K$309.83K$-1.76M$-1.59M$-1.48M$-4.80M$-1.80M$-1.62M$-1.51M$-1.59M$-5.01M$-4.35M$-4.11M$-3.63M$-4.38M$-3.39M$-7.10M
Low Forecast$248.77K$316.62K$398.03K$309.83K$-1.76M$-1.59M$-1.48M$-4.80M$-1.80M$-1.62M$-1.51M$-1.59M$-5.01M$-4.35M$-4.11M$-3.63M$-4.38M$-7.95M$-7.10M
Surprise %-------------------

Annovis Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Annovis Bio SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
SG&A-------------------
Avg Forecast-------------------
High Forecast-------------------
Low Forecast-------------------
Surprise %-------------------

Annovis Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANVS last annual SG&A of $NaN (undefined).

Annovis Bio EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
EPS-------------------
Avg Forecast$0.02$0.03$0.04$0.03$-0.16$-0.14$-0.13$-0.42$-0.16$-0.14$-0.13$-0.14$-0.44$-0.39$-0.36$-0.32$-0.39$-0.51$-0.63
High Forecast$0.02$0.03$0.04$0.03$-0.16$-0.14$-0.13$-0.42$-0.16$-0.14$-0.13$-0.14$-0.44$-0.39$-0.36$-0.32$-0.39$-0.30$-0.63
Low Forecast$0.02$0.03$0.04$0.03$-0.16$-0.14$-0.13$-0.42$-0.16$-0.14$-0.13$-0.14$-0.44$-0.39$-0.36$-0.32$-0.39$-0.70$-0.63
Surprise %-------------------

According to undefined Wall Street analysts, Annovis Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANVS previous annual EPS of $NaN (undefined).

Annovis Bio Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INABIN8bio$0.30$14.004566.67%Buy
RVPHReviva Pharmaceuticals$1.00$10.00900.00%Buy
NVAXNovavax$9.12$58.00535.96%Buy
CUECue Biopharma$1.49$5.00235.57%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
ANVSAnnovis Bio$8.73$25.67194.04%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
ABOSAcumen Pharmaceuticals$2.95$7.00137.29%Buy
IMNMImmunome$12.81$30.33136.77%Buy
ANIXAnixa Biosciences$3.45$7.50117.39%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
IOVAIovance Biotherapeutics$11.44$21.0083.57%Buy
MCRBSeres Therapeutics$0.81$1.2554.32%Buy
AVXLAnavex Life Sciences$7.30$11.0050.68%Buy
AXSMAxsome Therapeutics$87.25$117.8335.05%Buy
GRCLGracell Bio$10.25$6.00-41.46%Buy

ANVS Forecast FAQ


Yes, according to 4 Wall Street analysts, Annovis Bio (ANVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of ANVS's total ratings.

Annovis Bio (ANVS) average price target is $25.67 with a range of $21 to $30, implying a 194.04% from its last price of $8.73. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ANVS stock, the company can go up by 194.04% (from the last price of $8.73 to the average price target of $25.67), up by 243.64% based on the highest stock price target, and up by 140.55% based on the lowest stock price target.

ANVS's average twelve months analyst stock price target of $25.67 supports the claim that Annovis Bio can reach $13 in the near future.

1 Wall Street analyst forecast a $30 price target for Annovis Bio (ANVS) this month, up 243.64% from its last price of $8.73. Compared to the last 3 and 12 months, the average price target increased by 192.10% and increased by 194.04%, respectively.

Annovis Bio's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-9.629M (high $-9.629M, low $-9.629M), average SG&A $0 (high $0, low $0), and average EPS is $-0.852 (high $-0.852, low $-0.852). ANVS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $45.74M (high $45.74M, low $45.74M), average EBITDA is $0 (high $0, low $0), average net income is $1.27M (high $1.27M, low $1.27M), average SG&A $0 (high $0, low $0), and average EPS is $0.113 (high $0.113, low $0.113).